Management of breast cancer during pregnancy  by Rovera, Francesca et al.
ORIGINAL ARTICLE
International Journal of Surgery (2013) 11(S1), S64–S68
Contents lists available at ScienceDirect
International Journal of Surgery
journal homepage: www.journal-surgery.net
ORIGINAL ARTICLE
Management of breast cancer during pregnancy
Francesca Roveraa,b, Corrado Chiappaa,b, Alessandra Coglitored, Giorgio Maria Baratelli d, Anna Fachinetti a,b,
Marina Marelli a,b, Francesco Frattini a, Matteo Lavazzaa, Linda Basciallae, Stefano Rausei a, Luigi Boni a,
Adriana Dionigi Corbenc, Gianlorenzo Dionigi a, Renzo Dionigi a
a Unit of General Surgery, Circolo Teaching Hospital, University of Insubria, Varese, Italy
b Senology Research Center, University of Insubria, Varese, Italy
c Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA
d Senology Unit, Moriggia-Pelascini Hospital, Gravedona, Como, Italy
e Unit of Oncology, Circolo Teaching Hospital, University of Insubria, Varese, Italy




A B S T R A C T
Introduction: Pregnancy-associated breast cancer (PABC) is one of the most common malignancies during
pregnancy. Since maternal age at the time of pregnancy is increasing, PABC rate is expected to increase.
Diagnostic delays are common.
Methods: Retrospective observational study analysing twelve pregnant patients with breast cancer who
underwent surgical treatment during the period of February 2006 to June 2013 at theDepartment of Surgery I,
University of Insubria Varese.
Results: Themedian age of pregnant patientswas 34 y (range 28–44y). Three patientswere affected by BRCA1
mutation. In six patients diagnosis was made during gestation, in the other six patients breast cancer was
discovered during breastfeeding. Ten patients underwent breast-conserving surgery. Sentinel lymph node
biopsywas performed in six patients; in one of them it was positive so axillary dissectionwas simultaneuosly
performed. Six patients underwent axillary dissection ab initio. In all cases the histological type was invasive
ductal carcinoma; grade 3 in ten patients and grade 2 in two patients. Eleven of twelve patients received
adjuvant chemotherapy, one patient both adjuvant and neoadjuvant. In three cases also radiation therapy
was performed after delivery. In all cases healthy babies were born. Nine of twelve patients are still alive and
disease free, after a median follow-up of 20 months (range 3–52 months). Three patients died from systemic
progression of the disease.
Conclusion: There are no signiﬁcant series of patients in worldwide literature to develop standard protocols.
Pregnant women must be followed by a multidisciplinary team.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Pregnancy-associated breast cancer (PABC) is deﬁned as breast cancer
diagnosed during pregnancy or within one or two years after
delivery. 1,2
Breast cancer is the second most common malignancy diagnosed
during pregnancy, ranging from 1 in 1,000 to 1 in 3,000 pregnan-
cies 3,4; up to 3% of breast cancers are diagnosed in pregnantwomen 5
between the ages of 23 and 47 years (median age, 33 years). 6
However, the incidence is expected to increase as more women delay
childbearing.
1.1. Diagnosis
The delay in diagnosis is still a controversial issue in PABC; recent
studies report a delay in diagnosis of 1–3months. 7 During pregnancy
and lactation, the breast undergoes dramatic changes in response to
an increase in the circulating hormones estrogen, progesterone, and
prolactin, which all have a proliferative effect on glandular and ductal
tissue. 8 The breast changes can obscure detection of breast mass
for patients and physicians, leading to more advanced stages at
diagnosis than in the general population. 9,10 Clinical examination
of breasts during pregnancy is difﬁcult because the breast presents
increased density and ﬁrmness. Breast ultrasonography is the ﬁrst
diagnostic instrument used by clinicians when a breast mass and the
axillary area need to be assessed in a pregnantwoman, since it is non-
ionizing and has high sensitivity and speciﬁcity. 6,11 Mammography
has less sensitivity and is associated with a high false-negative rate;
but it remains a fundamental imaging tool in the evaluation of PABC.
Mammography exposes a fetus to only 0.004Gy, below the threshold
for a deterministic effect. 12 The use of breast magnetic resonance
1743-9191$ – see front matter © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
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imaging (MRI) is still controversial because the of the challenge
to discriminate malignant and physiologic hypervascularization
occurring during pregnancy and because gadolinium crosses the
placenta and is associated with fetal abnormalities in rats. 2 Magnetic
resonance imaging itself is associated with risks to the fetus. 13–17
The standard examination to obtain a histological diagnosis is
a core biopsy under local anesthesia, which can be done safely
during pregnancy with a sensitivity of around 90%. 11,18 Milk ﬁstulas
are rare. Gestational and puerperal hormones induce physiological
hyperproliferative changes of the breast, which could lead to a false
positive or false negative result with ﬁne-needle aspiration cytology.
Therefore, this procedure is not recommended during pregnancy. 19
Diagnostic over-interpretation is avoided when the pathologist is
aware that the patient is pregnant.
When breast cancer is diagnosed, an accurate staging of the
disease is needed. Chest X-ray is a safe procedure when appropriate
abdominal shielding is used, and exposes the fetus to 0.0001Gy.
Computed tomography (CT) scans of the abdomen are avoided at all
stages of pregnancy due to the dangerous levels of radiation exposure;
abdominal ultrasonography is a safe alternative in evaluating hepatic
and abdominal conditions; no overall consensus among authors has
been obtained for low-dose bone scan. Unenhanced MRI could be
performed in case of suspected liver or bone metastases. 5,6,20–22
1.2. Pathology
Invasive ductal carcinomas are the most common histological
subtype. 3,23,24 Tumors are usually high grade and lymphovascular
invasion is commonly seen. 3,9,22–25 Hormone receptor status is
commonly negative because pregnant women are even less likely
to be estrogen-receptor positive. 26 Numerous studies have found
that women with breast cancer in pregnancy have larger tumors and
are more frequently to have positive nodes, metastases and vascular
invasion. 1,2,9,23 Studieswith limited population also revealed a higher
expression of Her2/neu. 27,28
1.3. Genetics
Recent research indicates that women with a genetic predisposition
to breast cancer may be over-represented among pregnant patients
with cancer. Women diagnosed as having breast cancer before age
40 years, known BRCA1 and BRCA2 carriers were more likely to
develop cancer during pregnancy. Among BRCA mutation carriers,
high levels of circulating estrogens during pregnancy may accelerate
a malignant transformation that has already begun. 29,30
1.4. Treatment
The aim of treatment of PABC is the same as that for non-
pregnant patients with breast cancer: local control of the disease
and prevention of systemic metastases. During pregnancy, some
treatmentmodalities need to bemodiﬁed because of the potential for
adverse effects on the fetus.
1.4.1. Surgery
Surgery is the deﬁnitive treatment for PABC, and is the ﬁrst step of a
multidisciplinary approach to the tumor as in non-pregnant patients.
Surgery is safe and it can be performed in all trimesters of pregnancy
with minimal risk for the fetus. There are two main possible
strategies for breast surgery: radical modiﬁed mastectomy (RMM)
and conserving surgery, and for axilla lymph node (ALN) dissection
or sentinel lymph node biopsy (SLNB). The difference between these
two options is that after breast-conserving surgery, radiotherapy is
mandatory in order to decrease local recurrence; so a conservative
procedure ismainly considered in the last trimester. The survival rates
of both are similar. 6,31 SLNB in pregnant women is safe; recently
Gentilini showed the results of a study demonstrating the safety and
feasibility of this technique to be similar to that for non-pregnant
women. 32 RMM can be followed by an immediate reconstruction
of the breast with implants. Several reports concur that surgical
treatment is usually well accepted by patients without signiﬁcant
complications, either for themother or for the fetus. 22,23 An increased
risk of low birth weight infants is reported as a result of premature
labor or intrauterine growth retardation. 33
1.4.2. Radiotherapy
Radiation therapy is contraindicated during pregnancy; the exposure
of the fetus to ionizing radiation in utero, due to its teratogenic effects,
is not considered a safe therapeutic option. 34 Mental retardation is
themain risk after the 8th week of pregnancy, and children born after
having been exposed to radiation in utero have an increased risk of
childhood cancer. 35,36
1.4.3. Chemotherapy
Chemotherapy could be proposed as adjuvant or neoadjuvant treat-
ment. Cytotoxic chemotherapy should be avoided in the ﬁrst trimester
of pregnancy due to its high potential for teratogenicity during
organogenesis, possibility of spontaneous abortion or fetal malfor-
mations (ranging from 10–20%). 7,37–39 Beyond the ﬁrst trimester,
however, chemotherapy does not appear to signiﬁcantly increase the
risk of malformations. During later trimesters, the possibility of such
phenomena decreases to an acceptable level (up to 1.5%), allowing
adjuvant or neo-adjuvant regimens to be used. 40
Among the chemotherapeutic agents frequently used in breast
cancer, methotrexate is strongly contraindicated. 41,42 The terato-
genicity of ﬂuorouracil remains unclear. 43 Anthracyclines are con-
sidered safer than alkylating agents. 44 Alkylating factors and anti-
metabolites must also be avoided due to an increased rate of fetal
malformations. 45,46 Taxanes seem to be safe in the third trimester,
but are not recommended since there are no more data. 41 Long-term
effects of chemotherapy on offspring are unknown. 47 Chemotherapy
dosage during pregnancy is complicated by increased plasma volume,
increased hepatorenal function, decreased albumin concentration
and decreased gastric motility as well as the theoretical possibility
that the amniotic sacmight act as a third space. In addition, almost all
chemotherapy agents cross the placenta.
1.4.4. Hormonal therapy
Tamoxifen is not recommended during pregnancy. 5,26 There are no
reports of womenwith PABC receiving aromatase inhibitors although
teratogenic effects have been described in animal models. 48 Several
studies report up to 20% fetal abnormalities, including craniofacial
malformations and ambiguous genitalia. 5
1.4.5. Termination of pregnancy
Termination of pregnancy and postpartum delayed treatment are not
routinely recommended because they do not improve survival. 37
2. Patients and methods
From February 2006 to June 2013, twelve patients with PABC from a
single Clinical Center (Department of Surgery I, University of Insubria
Varese, Italy) were included in this retrospective observational study.
Data regarding epidemiology, patients and tumor characteristics,
lymphnodal status, lymphovascular invasion, treatment and follow-
up were collected in a database.
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Immunohistochemical evaluation of proliferative fraction (Ki-67
labelling index), estrogen (ER) and progesterone receptor (PgR)
expression and HER2/neu overexpression were performed according
to our standard technique. 49
All patients came to our attention after the discovery of newly
formed mammary mass or the presence of other clinical suspicions
at breast self-examination. These lesions were then investigated
with ultrasound, and subsequently with mammography, followed by
microhistology. The treatment and follow-up of these patients were
recorded, and all patients underwent check-ups every 4–6 months
after treatment.
All patients have been proposed various therapeutic strategies and
were informed that currently in the literature there is no evidence
that the interruption of pregnancy is able to increase overall survival.
Prior to surgery systemic staging was carried out including chest
X-ray and ultrasound of the abdomen together with anesthetic
assessment and a careful obstetric-gynecological examination.
The main follow-up of patients was obtained by serial outpatient
visits.
3. Results
Twelve women with breast cancer were included in the study; the
diagnosis was made in 6 cases during pregnancy (group 1) and in
the other 6 cases during lactation (group 2). In group 1, 2 patients
were in the ﬁrst trimester, 1 in the second trimester and 3 in the third
trimester, with mean gestational ages of 8, 23 and 33 weeks. The only
patient whose pregnant state was discovered concurrently with the
diagnosis of breast cancer chose voluntary interruption of pregnancy,
although all therapeutic possibilities were explained at length.
The median age of the pregnant patients was 34y (range 28–44y).
All patients underwent preoperative breast ultrasound and bilateral
mammography; in all cases the histological diagnosis was obtained
by core biopsy under local anesthesia. Chest radiograph and abdomen
ultrasound were also performed in all patients to investigate
metastatic disease and in any of these distant metastases were found.
The mean size of the primary tumor at the time of diagnosis was
3.3 cm (range 0.5–8.2 cm).
Conservative surgical therapy was performed in 4 cases in group 1
and in only 2 cases in group 2. In four pregnant patients sentinel
node biopsy was performed without any consequence to the fetus;
in all cases the lymph node was negative. In a lactating woman,
however, it was necessary to perform axillary lymph node dissection
for the presence of micrometastases in the sentinel node. Six patients
underwent axillary dissection ab initio for metastatic axillary disease
discovered byphysical examination andultrasonography; 2 in group1
and 4 in group 2. Hormone status receptors were negative for
3 patients in group 1 and 4 in group 2.
In our study 3 patients were affected by genetic mutation of the
BRCA1 gene.
All patients included in the study had invasive ductal carcinoma,
grade 3 in 10 patients and grade 2 in 2 patients. In 4 cases of group 1
the diagnosis was made after the discovery of a palpable mass during
breast self-examination, while in 2 patients the tumor was diagnosed
during regular check-up.
The 4 patients who underwent surgery during pregnancy have
healthy babies without any complication.
One patients did not receive any chemotherapy. After completion
of pregnancy, nine patients received full-dose combination adjuvant
chemotherapy, including alkylators, anthracyclines and taxanes; two
patients received both neoadjuvant and adjuvant chemotherapy.
Breast external radiotherapy was implemented in three patients
after delivery.
Delivery was cesarian in most of patients, one patient delivered
spontaneusly at 39 weeks of gestation and one patient underwent
induction.
All patients underwent suppression of breastfeeding with cabergo-
line to prevent accumulation of lipophilic agents such as taxanes in
the milk.
In 3 patients distant metastases occurred: two had liver metastases
and another had both liver and lung metastases. These 3 patients
died of metastatic breast cancer 12, 27 and 30 months after surgery,
respectively.
At themoment of writing, after amean follow-up of 20months, the
other patients are well without signs of local or distant recurrence.
4. Discussion
The incidence of breast cancer in pregnancy is likely to increase due to
the trend ofwomen,mainly inmodern society, to postpone pregnancy
to older age, between 35 and 45 years, a period of fertile age in which
there is an increasing incidence of breast cancer.
The precise deﬁnition of the extent of disease, the patient’s desire to
complete gestation, and information on the maturity and integrity of
the fetus, are only some of the factors to be taken into account in the
planning of the therapeutic program during pregnancy; it is therefore
essential to exactly know the clinical behavior and the biology of
breast cancer in pregnant patients in order to reach the best treatment
for each patient.
There is no evidence that the interruption of pregnancy modiﬁes
the prognosis of these patients in terms of recurrence or survival. 50
Surgery may be conservative or radical. The review by Woo et al. 2
concluded that modiﬁed radical mastectomy with axillary dissection
is considered the best choice for patients diagnosed with breast
cancer in the ﬁrst quarter, who decide to continue pregnancy, in order
to eliminate the necessity of radiation therapy, which can only be
administered after delivery. 51 Conservative surgery can be proposed
if technically possible; there are some ongoing studies evaluating the
feasibility and the potential side effects on the fetus of intraoperative
radiotherapy (ELIOT – electron beam intraoperative radiotherapy) in
the ﬁrst and second quarter. 52
There are conﬂicting opinions on the use of sentinel lymph node
biopsy in pregnancy with radioactive technetium; Kaufmann et al. 53
do not recommend its use for the supposed teratogenic effect, while
Gentilini et al. published data demonstrating the safety of this
procedure. 32
In the literature there are very few data on hormone therapy
conducted in pregnant patients, but the use of these drugs is
contraindicated during pregnancy. 54 Chemotherapy given in the
ﬁrst trimester is associated with an increased risk of miscarriage
and congenital malformations of the fetus, and it is therefore
contraindicated.
Encouraging data are published on the administration of chemo-
therapy during the second and third trimester. 55 There are no
reported cases of increased malformation in infants of mothers who
received chemotherapy during pregnancy. Cases of low birthweight
are reported as a result of intrauterine growth retardation and
premature delivery. 10
Delivery must be completed not earlier than 3 weeks after the last
cycle of chemotherapy, to reduce maternal and fetal hematological
toxicity. The short-term follow-up of infants is reassuring, but results
have yet to be published on neonatal follow-up in the long term.
Some authors argue that pregnancy is not considered a risk factor
for breast cancer, at the same stage and age 1; on the other hand
someauthors considered that prognosis of patientswith breast cancer
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diagnosed in pregnancy is worse than for the control population,
in terms of both recurrence and survival. 9,56 In a report on a large
series of breast cancer cases during pregnancy (797 cases) versus
4,177 controls, from the California Cancer Registry, the authors also
argue that controlled for stage, race, tumor size, type of surgery and
hormonal status, pregnancyworsens the prognosis of the tumor, with
a relative risk of 1.14. 57
Generally cancers diagnosed at a young age are more aggressive
than those affecting women of older age, and for this reason breast
cancer in pregnancy is generally more aggressive and often occurs in
more advanced stage than in non-pregnant women.
Some authors suggest that the morphological and immuno-
histochemical characteristics may change related to the period:
pregnancy, breast-feeding or after delivery. 58
5. Conclusions
The management of patients with cancer during pregnancy requires
the effort of a multidisciplinary team that is able to offer to these
patients the best options and the necessary psychological support in
an extremely delicate period of their life.
The worst prognosis of these patients is probably related more to
the biological characteristics of the tumor than to pregnancy itself.
Taking into account that the diagnosis of cancer during pregnancy
remains an infrequent event and that the effects of therapy on the
unborn child are not yet fully known, it would be desirable for
all cases to be referred to specialized centers, in order to establish
national and international registries that ultimately will provide
deeper knowledge of the problem and a more adequate counseling
of patients. A project is ongoing, in collaboration with the Breast
International Group (BIG), to create a European registry that will help
us to increase our knowledge in this ﬁeld.
The diagnosis of breast cancer during pregnancy has high psycho-
logical impact on the patient’s life, her family, and even the multi-
disciplinary team. The conﬂict between giving life and questioning it
creates a tension that needs great clinical wisdom and respect for the
deepest feelings of the patient, but also awareness of its limitations in
the face of decisions that are never simple. The right balance between
maximum beneﬁt to the patient and minimal harm to the fetus is not
always achievable; the difﬁcult management of this situation needs
the uncommon ability to listen and the humility tomake comparisons
with other colleagues to ﬁnd the best solution. The decision of the
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